The Pennant Group, Inc.
25.03-0.86 (-3.32%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · PNTG · USD
Key Stats
Market Cap
865.09MP/E (TTM)
32.51Basic EPS (TTM)
0.77Dividend Yield
0%Recent Filings
8-K
Pennant expands acquisition deal
The Pennant Group amended its April 2025 purchase agreement with UnitedHealth Group and Amedisys on October 1, 2025, expanding the acquisition of home health, hospice, and palliative care assets to include additional Tennessee entities and locations. The deal price rose from $102,484,000 to $146,531,160, boosting Pennant's service footprint in a key market. Yet regulatory hurdles loom for shared licensure sites. This bolsters capacity amid growing demand.
8-K
Pennant closes Southeast acquisition
The Pennant Group closed its $146.5 million cash acquisition of 54 home health, hospice, and personal care locations in Tennessee, Georgia, and Alabama from UnitedHealth Group and Amedisys on October 1, 2025, stemming from their antitrust settlement. This deal expands Pennant's footprint into the Southeast, with two-thirds of revenue from home health and one-third from hospice, supported by a transition services agreement for seamless integration. Pennant eyes further growth in these sectors. Expansion boosts regional presence.
10-Q
Q2 FY2025 results
Pennant Group posted solid Q2 results, with revenue climbing 30.1% year-over-year to $219.5M, fueled by acquisitions and organic gains in home health and hospice admissions, while senior living revenue per unit rose 8.3%. Operating income edged up 20.5% to $11.5M, though margins dipped slightly to 5.3% amid higher costs; diluted EPS improved to $0.20 from $0.18, reconciling cleanly with 35,372 weighted shares. Acquisitions added five home health agencies, four hospice agencies, and four senior living communities in H1, boosting goodwill to $156.6M and indefinite-lived intangibles to $117.2M, with $47.6M cash outlay for business buys. Cash stood at $14.4M, free cash flow at $8.4M (derived), and $37M in revolving debt at 6.08%, with $208.8M availability under covenants. Yet regulatory pressures on reimbursements loom large.
8-K
Pennant Q2 revenue surges 30%
The Pennant Group reported Q2 2025 revenue of $219.5 million, up 30.1% year-over-year, driven by 32.5% growth in home health and hospice to $166.0 million and 23.1% in senior living to $53.5 million. Net income rose 24.5% to $7.1 million, with adjusted EBITDA climbing 24.5% to $16.4 million amid higher admissions and stable occupancy. Momentum persists. Updated 2025 guidance projects revenue of $852.8-$887.6 million and adjusted EPS of $1.09-$1.15, yet regulatory reimbursement risks loom.
8-K
Annual meeting elects directors
The Pennant Group held its annual stockholder meeting on May 16, 2025, electing Stephen M.R. Covey and Suzanne D. Snapper as Class III directors until 2028, with Snapper securing strong support while Covey faced notable opposition. Stockholders approved an amendment for officer exculpation under Delaware law, ratified the Amended and Restated 2019 Omnibus Incentive Plan, and confirmed Deloitte & Touche as auditors for 2025. Say-on-pay passed advisory approval. Elections reveal board tensions.
IPO
Website
Employees
Sector
Industry
AVAH
Aveanna Healthcare Holdings Inc
9.86+0.05
BKD
Brookdale Senior Living Inc.
8.95+0.12
EHAB
Enhabit, Inc.
8.50-0.03
ENSG
The Ensign Group, Inc.
182.70-2.94
HCA
HCA Healthcare, Inc.
468.40+1.94
HCSG
Healthcare Services Group, Inc.
18.81-0.42
INNV
InnovAge Holding Corp.
4.82-0.26
NHC
National HealthCare Corporation
120.85-1.15
PACS
PACS Group, Inc.
12.44+0.02
SNDA
Sonida Senior Living, Inc.
25.73-0.44